AI assistant
Axogen, Inc. — Director's Dealing 2023
Jun 6, 2023
32414_dirs_2023-06-05_a3775554-e903-4fcb-84c8-f7be19faf76b.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Axogen, Inc. (AXGN)
CIK: 0000805928
Period of Report: 2023-06-01
Reporting Person: Freitag Gregory Gene (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2023-06-01 | Common Stock | S | 12500 | $8.65 | Disposed | 319615 | Direct |
| 2023-06-01 | Common Stock | S | 29480 | $8.74 | Disposed | 290135 | Direct |
| 2023-06-01 | Common Stock | M | 6459 | — | Acquired | 296594 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2023-06-01 | Restricted Stock Units | $ | M | 6459 | Disposed | Common Stock (6459.0) | Direct |
Footnotes
F1: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $8.57 to $8.75 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F2: The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $8.66 to $8.83 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F3: This reflects the number of restricted stock units that vested on June 1, 2023.
F4: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.
F5: Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2023, one year from the anniversary of the grant date.